Welcome to LookChem.com Sign In|Join Free
  • or
1-(3,4-dimethoxybenzyl)-4-(4-nitrophenyl)piperazine is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

414877-58-0

Post Buying Request

414877-58-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

414877-58-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 414877-58-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,1,4,8,7 and 7 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 414877-58:
(8*4)+(7*1)+(6*4)+(5*8)+(4*7)+(3*7)+(2*5)+(1*8)=170
170 % 10 = 0
So 414877-58-0 is a valid CAS Registry Number.

414877-58-0Relevant academic research and scientific papers

In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2)

Labrie, Philippe,Maddaford, Shawn P.,Lacroix, Jacques,Catalano, Concettina,Lee, David K.H.,Rakhit, Suman,Gaudreault, Rene C.

, p. 3854 - 3868 (2007)

Synthesis and in vitro cytotoxicity assays of new anthranilamide MDR modulators have been performed to assess their inhibition potency on the P-glycoprotein (P-gp) transporter. Previous studies showed that the replacement of the aromatic spacer group betw

Nitrogen-containing heterocycle derivatives and applications thereof

-

Paragraph 0218-0220, (2018/03/24)

The invention discloses nitrogen-containing heterocycle derivatives and applications thereof, relates to compounds of a general formula (V), a preparing method thereof and applications of the compounds in medicines, and more particularly relates to compound derivatives of compounds shown as the general formula (V), a preparing method thereof and uses of the derivatives in medicines preventing andtreating hyperlipemia, hypercholesterolemia, hypertriglyceridemia, fatty degeneration of liver, diabetes mellitus type 2, hyperglycemia, obesity or insulin resistance and metabolic syndrome and resisting antitumor, with the derivatives being adopted as therapeutic agents. The compounds disclosed by the invention can also reduce total cholesterol, LDL-cholesterol and triglyceride, can increase liver LDL receptor expression, and inhibit PCSK9 expression.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 414877-58-0